Clinical Trials Sponsored by Provention Bio, a Sanofi Company

Total 995 results

Provention Bio, a Sanofi Company

Active, not recruiting

PRV-015 in Gluten-free Diet Non-responsive Celiac Disease (PROACTIVE)

Celiac Disease

United States, Canada, Netherlands, Spain
Provention Bio, a Sanofi Company

Completed

At-Risk for Type 1 Diabetes Extension Study (TN-10 Extension)

Diabetes Mellitus, Type 1

United States
Provention Bio, a Sanofi Company

Recruiting

Teplizumab in Pediatric Stage 2 Type 1 Diabetes (PETITE-T1D)

Diabetes Mellitus, Type 1

United States
Provention Bio, a Sanofi Company

Active, not recruiting

Recent-Onset Type 1 Diabetes Extension Study Evaluating the Long-Term Safety of Teplizumab (PROTECT Extension)

Diabetes Mellitus, Type 1

United States, Belgium, Canada, Czechia, France, Germany, Poland, United Kingdom
Provention Bio, a Sanofi Company

Active, not recruiting

PRV-3279-2a Trial in Systemic Lupus (PREVAIL-2)

Systemic Lupus Erythematosus

United States, China, Hong Kong, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Recruiting

BEYFORTUS™ (Nirsevimab) Effectiveness Against Medically-Attended RSV Events in Infants (BEAR Study) (BEAR)

Respiratory Syncytial Virus

United States
Sanofi Pasteur, a Sanofi Company

Recruiting

Efficacy, Immunogenicity, and Safety Study of a Respiratory Syncytial Virus Vaccine in Infants and Toddlers (PEARL)

RSV Immunisation

United States, Argentina, Honduras
Sanofi Pasteur, a Sanofi Company

Recruiting

Study of the Safety and Immune Response of an Investigational mRNA Vaccine for the Prevention of Respiratory Syncytial Virus and/or Human Metapneumovirus in Participants Aged 18 to 49 Years and 60 Years and Older

Healthy Volunteers | Respiratory Syncytial Virus Infection | Metapneumovirus Infection

Australia, United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Quadrivalent Influenza mRNA Vaccine MRT5410 in Adult Participants 18 Years of Age and Older

Influenza Immunization

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Purified Vero Rabies Vaccine Compared With Two Reference Rabies Vaccines, Given in a Pre-exposure Regimen to Children and Adults and as Single Booster Dose to a Subset of Adults (VRV12)

Rabies (Healthy Volunteers)

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older

Healthy Volunteers | Influenza Immunization

United States
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Surveillance of Suspected Dengue Cases for Access to Care for Subjects Identified as Seronegative or Undetermined Before Receiving CYD Dengue Vaccine in Previous Clinical Studies in Colombia (CYD00082)

Dengue Fever

Colombia
Sanofi Pasteur, a Sanofi Company

Terminated

Study With Quadrivalent Recombinant Influenza Vaccine (RIV4) Compared With Egg-Based Quadrivalent Influenza Vaccine (IIV4) in Participants Aged 3 to 8 Years

Influenza Immunization

United States, Denmark, Poland, Spain
Sanofi Pasteur, a Sanofi Company

Terminated

Study of mRNA Vaccine Formulation Against COVID-19 in Healthy Adults 18 Years of Age and Older (VAW00001)

COVID-19

United States, Australia, Brazil, Honduras
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US

Healthy Volunteers (Meningococcal Infection)

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of Shenzhen Quadrivalent Inactivated Influenza Vaccine Versus the Shenzhen Trivalent Inactivated Influenza Vaccine in Chinese Subjects From 6 Months of Age

Influenza

China
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of a Novel Multicomponent Meningococcal Group B Vaccine When Given Alone or With Other Licensed Vaccines in Adults, Adolescents, Toddlers and Infants

Meningococcal Immunisation

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively (GRC00097)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study on Prescribers' Knowledge and Understanding of Safety Messages Following Dengvaxia® Product Information Update (DNG00042)

Dengue Virus Infection

France
Sanofi Pasteur, a Sanofi Company

Completed

Study of Purified Vero Rabies Vaccine Compared With a Reference Rabies Vaccine as Simulated Rabies Post-Exposure Prophylaxis in Adult and Pediatric Population in Thaïland

Rabies (Healthy Volunteers)

Thailand
Sanofi Pasteur, a Sanofi Company

Active, not recruiting

Study of Monovalent and Bivalent Recombinant Protein Vaccines Against COVID-19 in Adults 18 Years of Age and Older (VAT00008)

COVID-19

United States, Colombia, Ghana, Honduras, India, Japan, Kenya, Mexico, Nepal, Nigeria, Sri Lanka, Uganda, Ukraine
Sanofi Pasteur, a Sanofi Company

Suspended

Study on a High-Dose Quadrivalent Influenza Vaccine Compared With Standard-Dose Quadrivalent Influenza Vaccine in Children 6 Months Through 35 Months of Age (QHD00014)

Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of DTwP-HepB-Hib-IPV (SHAN6™) Vaccine Administered Concomitantly With Routine Pediatric Vaccines to Healthy Infants and Toddlers in Thailand

Pertussis Immunisation | Diphtheria Immunisation | Tetanus Immunisation | Pneumococcal Immunisation | Hepatitis B Immunisation | Polio Immunisation | Haemophilus Influenzae Type B Immunisation | Rotavirus Immunisation

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity in Adults of Revaccination With Adacel® Vaccine 10 Years After a Previous Dose

Pertussis | Whooping Cough | Tetanus | Diphtheria

United States, Canada
Sanofi Pasteur, a Sanofi Company

Completed

A Study to Describe the Safety Profile and Compare the Immune Response of 4 Different Formulations of an Investigational Tdap Vaccine When Compared to Licensed Tdap Vaccine in Young Adults in Canada

Tetanus Immunisation (Healthy Volunteers) | Diphtheria Immunisation (Healthy Volunteers) | Pertussis Immunisation (Healthy Volunteers)

Canada
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Multi-Dose Quadrivalent Influenza Vaccine

Influenza

Mexico
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV/Hib Vaccine Primary & Booster Vaccinations Versus Co-administration of DTaP-IPV and Hib Vaccine in Japanese Infants

Pertussis | Tetanus | Diphtheria | Bacterial Meningitis | Poliomyelitis

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Observational Safety Study of Menactra® Administered Under Standard Health Care Practice in the Russian Federation

Meningitis | Meningococcal Infections | Meningococcal Meningitis

Russian Federation
Sanofi Pasteur, a Sanofi Company

Completed

Association of Host Genetics With Vaccine Efficacy and Study of Immune Correlates of Risk From a Tetravalent Dengue Vaccine

Dengue Fever | Dengue Haemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Dose-ranging Study of an Investigational Yellow Fever Candidate Vaccine in Adults (VYF01)

Yellow Fever (Healthy Volunteers)

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Single Dose or Two Doses of a Quadrivalent Influenza Vaccine in Subjects Aged 6 Months or Older in India

Influenza

India
Sanofi Pasteur, a Sanofi Company

Completed

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Taiwanese Adults 65 Years of Age and Older

Influenza (Healthy Volunteers)

Taiwan
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's Combined Vaccine Given as a Three-Dose Primary Series at 2, 3,4 Months of Age and Followed by a Booster Dose Given at 16 to 17 Months of Age in Vietnamese Infants Who Previously Received a Dose of Hepatitis B Vaccine at Birth or Within 1 Week After Birth

Hepatitis B | Pertussis | Tetanus | Diphtheria | Poliomyelitis | Haemophilus Influenzae Type b

Vietnam
Sanofi Pasteur, a Sanofi Company

Completed

DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants

Hepatitis B | Pertussis | Tetanus | Diphtheria | Polio | Human Immunodeficiency Virus Infection

South Africa
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Tetravalent Dengue Vaccine in Healthy Adult Subjects Aged 18 to 45 Years in India

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

India
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of an Investigational Quadrivalent Meningococcal Conjugate Vaccine in Adults 56 Years and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis

United States, Puerto Rico
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Quadrivalent Meningococcal Conjugate Vaccine in Subjects Aged 56 and Older

Meningitis | Meningococcal Infections | Meningococcal Meningitis | Invasive Meningococcal Disease

United States
Sanofi Pasteur, a Sanofi Company

Completed

Safety and Immunogenicity of Fluzone® Quadrivalent and Fluzone® High-Dose, Influenza Vaccines

Influenza | Flu

United States
Sanofi Pasteur, a Sanofi Company

Completed

Long-Term Study of Hospitalized Dengue & Safety in Thai Children Included in a Tetravalent Dengue Vaccine Efficacy Study

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Thailand
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Fluzone® Quadrivalent, Southern Hemisphere 2015 Formulation (Intramuscular Route)

Influenza

Philippines
Sanofi Pasteur, a Sanofi Company

Terminated

Study of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Adacel® in Healthy Subjects

Dengue Fever | Dengue Hemorrhagic Fever

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of Sanofi Pasteur's CYD Dengue Vaccine in Healthy Children and Adolescents in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever | Dengue Virus

Puerto Rico, Colombia, Mexico, Honduras
Sanofi Pasteur, a Sanofi Company

Completed

Immunogenicity and Safety of a Tetravalent Dengue Vaccine Booster Injection in Subjects Who Previously Completed a 3-dose Schedule

Dengue Fever | Dengue Hemorrhagic Fever

Singapore
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Novel Tetravalent Dengue Vaccine in Healthy Children and Adolescents Aged 9 to 16 Years in Latin America

Dengue | Dengue Fever | Dengue Hemorrhagic Fever

Colombia, Puerto Rico, Brazil, Honduras, Mexico
Sanofi Pasteur, a Sanofi Company

Completed

Sanofi Pasteur Quadrivalent Influenza Vaccine (QIV) Pregnancy Registry

Pregnancy | Influenza

United States
Sanofi Pasteur, a Sanofi Company

Completed

Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan

Clostridium Difficile Infection

Japan
Sanofi Pasteur, a Sanofi Company

Completed

Descriptive, Post-marketing, Passive Surveillance Safety Study of ADACEL™ Vaccine

Pertussis

United States
Sanofi Pasteur, a Sanofi Company

Completed

A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in the Philippines

Cholera

Philippines
Sanofi Pasteur, a Sanofi Company

Completed

Comparative Study of Immunogenicity and Safety of Flu-ID Vaccine Versus Flu-IM Vaccine

Influenza

Belgium, France
Sanofi Pasteur, a Sanofi Company

Completed

A Study of the Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Subjects Aged 65 Years and Older

Influenza

United States

3

Subscribe